Top 12 Most Expensive Drugs in the US Healthcare Market

Cell and Gene Therapy

Biohaven’s Troriluzole Failure; Daiichi/ ...

Biohaven's Troriluzole Dwindles Again In Alzheimer’s After Anxiety  Biohaven Pharmaceuticals had put too much faith in its third-generation prodrug, Troriluzole. The company has tested the eff...

Jan 19, 2021

recent-pharma-biotech-news-updates-for-fosun-biontech-biomarin-Boston-Scientific
Fosun-BioNTech’s COVID-19 vaccine; Multiple Sclerosis research update; Vosoritide nabs FDA review; FDA nods to paclitaxel-coated Ranger balloon for PAD

FDA nods Boston Scientific's paclitaxel-coated Ranger balloon for peripheral artery disease Boston Scientific has received the FDA approval for its Ranger paclitaxel-coated balloon, designed to restrict a patient's systemic exposure to the chemotherapy used to reduce the closure of reopened arteries. The slim...

Find More
recent-pharma-news-and-updates-for-novartis-gsk-exact-sciences-eqrx
Novartis taps Molecular Partners to combat COVID-19; GSK culls phase 2 asthma drug; Exact Sciences acquires Thrive for $ 2.15 B; EQRx-CStone’s deal for checkpoint inhibitors

Novartis taps Molecular Partners for a novel approach to combat COVID-19 Novartis is spending USD 69 million upfront on a pair of experimental drugs from Molecular Partners. The pact is for MP0420 and MP0423, two antivirals out of the biotech’s so-called DARPin tech, which Molecular Partners says that it has ...

Find More
Pharma news for Bayer, Novartis, Forma, AskBio
Bayer eyes AskBio’s Gene Therapies; Novartis’ Iptacopan; Forma’s IDH1-Mutated AML Therapy; EpicGenetics teams up with Mayo Clinic

Bayer Set to Fork Over USD 4 Billion for AskBio’s Gene Therapies Germany-based Bayer is set to acquire North Carolina-based Asklepios BioPharmaceutical (AskBio) with motives to get its hands on its gene therapies.  Bayer will pay USD 2 billion in upfront payment in exchange for AskBio's AAV-based gene th...

Find More

More Views & Analysis

Pharma news fro GSK, InCarda, BridgeBio
GSK’s RSV vaccine; SparingVision’s interest in gene therapy; InCarda’s raise; BridgeBio’s R&D deal

GSK eyes robust immune response from RSV vaccine  Cold viruses mostly do not get much attention in terms of R&D. They usually make humans feel miserable for a few days, and later than clear up. However, some cold viruses can hit vulnerable people much harder, which leads to pneumonia and hospitalizations. Th...

Find More

recent-pharma-happenings-for-amylyx-orca-lyell-ionis
Amylyx’s neuron-protecting drug slows ALS decline; Antisense drugs could help fight ALS and dementia; CAR-T research updates; Orca and Lyell announces research partnership

Amylyx's neuron-protecting drug slows ALS decline in the late-phase study A novel combination of compounds has displayed that it can help decrease amyotrophic lateral sclerosis (ALS) by supporting the brain's neurons' inner workings. After six months of treatment, AMX0035 of Amylyx Pharmaceuticals demonstrate...

Find More

pharma-news-updates-for-biomarin-gilead-alzheon
FDA rejects BioMarin’s Valoctocogene Roxaparvovec; J&J inks $6.5B deal; Alzheon bags $47M; Research updates on diabetes

FDA rejects BioMarin's gene therapy and Gilead's filgotinib over concerns The FDA refused to approve BioMarin's hemophilia A gene therapy valoctocogene roxaparvovec. The U.S. regulator that had earlier told there was no requirement of an AdComm for the drug, aka, valrox, has issued a complete response (CRL) lett...

Find More

pharma-news
Startup focuses tumors with CAR-T; AbCellera grabs USD 105M; Gilead inks USD 2B deal; GSK’s anti-BCMA antibody receives a boost

The startup focuses on glioblastoma tumors with CAR-T therapy. CAR-T technology that involves genetically modifying a patient’s immune cells to recognize and attack cancer. However, while the innovation has helped patients with certain blood malignancies, progress in solid tumors remains restricted. The scien...

Find More

pharma-news
CanSino deals with Precision; Atea raises USD 215 M; Applied Molecular Transport targets for USD 100 M IPO; Cell therapy repairs multiple sclerosis in mice

CanSino adds mRNA with Precision NanoSystems  CanSino Biologics is already evaluating a recombinant coronavirus vaccine in China. However, it is adding the mRNA to COVID-19 vaccine through a licensing agreement with Precision NanoSystems. The partners will work on an mRNA nanoparticle vaccine for COVID-1...

Find More

CAR-T cell therapy market for Non-Hodgkin lymphoma
CAR-T cell therapy market for Non-Hodgkin lymphoma: Future prospects, and untapped opportunities

As per DelveInsight, the CAR T-Cell Therapy Market size for Non-Hodgkin lymphoma in the 6MM (the US, EU5 (the UK, Germany, France, Italy and Spain)) is expected to be USD 2796.2 Million by 2030. During the course of past decades, with the advancement in technology and a clear understanding of the molecular patho...

Find More

Metachromatic Leukodystrophy (MLD) is a rare hereditary disease characterized by the accumulation of.....

Find More

An autosomal recessive disorder, Ataxia Telangiectasia, affects a person's nervous system, immune sy.....

Find More

Over the years, the Oncology domain has experienced the entry of several treatment approaches. Thera.....

Find More

Progressive Supranuclear Palsy (PSP) is a rare progressive disorder resulting from damage that occur.....

Find More

Gastroesophageal Reflux Disease (GERD, also known as chronic acid reflux) is a digestive disorder in.....

Find More

According to WHO, Chronic Obstructive Pulmonary Disease (COPD) is the third leading cause of death g.....

Find More